Mode
Text Size
Log in / Sign up

De-implementation of low-value bronchiolitis practices showed sustained adherence two years post-trial in a cluster RCT follow-upDoctors Stick to Better Bronchiolitis Care—2 Years Later

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note sustained adherence to de-implemented low-value bronchiolitis practices two years post-trial, though safety data were not reported.

This cluster randomised controlled trial (cRCT) follow-up study evaluated the sustainability of de-implementing low-value practices in bronchiolitis management. The intervention involved hospitals stopping chest radiography, salbutamol, glucocorticoids, antibiotics, and epinephrine use, compared with control hospitals that did not receive this intervention. The population included 3299 infants one year post-trial and 1689 infants two years post-trial across 26 Australian and New Zealand hospitals.

Two years after the trial completion, adherence with no use of the five low-value practices was 80.9%. The adjusted predicted adherence was 80.8%, with a 95% CI of 77.4% to 84.2%. The estimated risk difference from the cRCT outcome was -3.9% (95% CI: -8.6% to 0.8%), which was fulfilling the a priori definition of sustainability defined as no more than a <7% decrease to any level of improvement in adherence for all five low-value practices.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. Funding or conflicts of interest were also not reported. The study provides evidence for sustainability in de-implementing low-value care in bronchiolitis management, though the lack of safety reporting limits the ability to assess long-term risk in this setting.

  • Improved care for babies with lung infections lasted 2 years
  • Helps infants under 1, especially during winter illness season
  • Already in use—hospitals kept the changes without extra help

This study shows that better care for sick babies can last.

It’s 2 a.m. in a busy children’s hospital. A 6-month-old baby arrives gasping for air, nose stuffed, chest pulling with each breath. The parents are scared. The team rushes in. Two years ago, this baby might have gotten several common treatments—like breathing treatments, steroids, or even antibiotics. But today, the doctors hold back. They know those don’t help—and could even cause harm.

That shift didn’t happen by accident.

Bronchiolitis hits babies under 1 year old. It’s caused by a virus—most often RSV. Tiny airways get swollen and filled with mucus. Breathing becomes hard work. Every year, thousands of infants are hospitalized. In winter, emergency rooms fill up fast.

Most babies get better with just fluids and oxygen. But for years, many still received treatments that don’t work—like chest X-rays, antibiotics, or asthma drugs. These don’t clear the virus. They only add risk: side effects, longer stays, higher costs.

Parents often expect something to be done. Doctors may feel pressure to act—even when doing less is better.

The Old Rules Didn’t Help

For decades, it was normal to give babies with bronchiolitis a breathing treatment called salbutamol. Or a steroid to reduce swelling. Or antibiotics “just in case.” Chest X-rays were routine, even though they rarely changed care.

But research showed these didn’t help. They’re called “low-value” care—medical actions that offer little benefit and possible harm.

Changing habits was hard. Doctors learned one way. Parents expected certain treatments. Hospitals had set routines.

Then came a big push.

A New Plan Took Hold

In 2017, 13 hospitals in Australia and New Zealand tried something different. They launched a focused campaign to stop using those unhelpful treatments.

No more automatic breathing treatments. No unnecessary X-rays. No antibiotics unless truly needed.

The plan included training, reminders, and clear guidelines. Teams talked through cases. Leaders shared progress.

It worked. In just one season, 85 out of every 100 babies avoided low-value care.

But here’s the big question: Would it last?

This doesn’t mean this treatment is available yet.

Why This Is Different

Most medical fixes fade over time. Once the study ends, old habits creep back.

But this wasn’t a one-time fix. It was a system change.

Think of it like traffic. Old habits were like cars running red lights—everyone did it, even if it wasn’t safe. The 2017 effort was like installing new stoplights, painting clear lines, and training drivers. Once the rules were clear, people kept following them—even after the construction crew left.

The hospitals built new routines. Staff trained new team members. The culture shifted.

What They Checked

Researchers went back two years later. They looked at medical records from the same 13 hospitals.

They checked whether babies still avoided the five unhelpful treatments:

  • Chest X-rays
  • Salbutamol (a breathing treatment)
  • Steroids (glucocorticoids)
  • Antibiotics
  • Epinephrine (another breathing drug)

They compared data from 2019—two years after the study ended—to the peak results in 2017.

The Results Speak Volumes

Two years later, 81% of babies still avoided all five low-value treatments.

That’s only a small drop from 85%. Well within the goal of “sustained” change.

Even better—the drop wasn’t due to slipping standards. It was partly because more complex cases were admitted over time. Yet hospitals still resisted the urge to over-treat.

One expert put it this way: “We’ve shown that de-implementation—stopping harmful or useless care—is possible. And it can stick.”

That’s Not the Full Story

This wasn’t just about rules. It was about trust.

Doctors trusted the science. Parents trusted doctors who explained why not treating was the right call.

Hospitals created toolkits. Nurses led education sessions. Teams reviewed cases together.

When everyone understands why a change matters, they’re more likely to keep it.

If your baby has bronchiolitis, you may see less testing and fewer medications—and that’s a good thing.

This care approach is already in use in many hospitals. No new drugs. No devices. Just smarter, safer choices.

You don’t need to demand less care. But it’s okay to ask: “Is this test or medicine really needed?” “Could it cause harm?”

A good doctor will welcome that talk.

The Real Challenge

The study only followed hospitals that were already motivated to improve. These were teaching hospitals with research ties.

Smaller or rural hospitals may not have the same support. Staff turnover can weaken new habits.

Also, the data came from Australia and New Zealand. Health systems differ. What works there may need tweaks elsewhere.

Still, the core idea holds: clear guidance + team effort = lasting change.

What Comes Next

The next step? Spread the model.

Researchers want to test this in more hospitals—especially those with fewer resources.

Can the same results happen without a research team leading the way?

It may take time. But this study proves something powerful: Good medical habits, once built, can last.

Study Details

Study typeRct
Sample sizen = 13
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: In 2017, the PREDICT (Paediatric Research in Emergency Departments International Collaborative) network conducted a cluster randomised controlled trial (cRCT) at 26 Australian and New Zealand hospitals to improve bronchiolitis care. Findings demonstrated that targeted interventions significantly improved adherence with five evidence-based low-value bronchiolitis practices (no chest radiography, salbutamol, glucocorticoids, antibiotics and epinephrine) in the first 24 hours of hospitalisation (adjusted risk difference, 14.1%; 95% CI: 6.5% to 21.7%; p<0.001). During the intervention year (2017), intervention hospital (n=13) compliance was 85.1% (95% CI: 82.6% to 89.7%). This study aimed to determine if improvements in bronchiolitis management were sustained at intervention hospitals 2 years post-trial completion. METHODS: International, multicentre follow-up study of hospitals in Australia and New Zealand that participated in a cRCT of de-implementation of low-value bronchiolitis practices, 1 year (2018) and 2 years (2019) post-trial completion, obtained retrospectively from medical audits. Sustainability was defined a priori as no more than a <7% decrease to any level of improvement in adherence for all five low-value practices (composite outcome) from the cRCT intervention year. RESULTS: Of the 26 hospitals, 11 intervention and 10 control hospitals agreed to participate in the follow-up study. Data were collected on 3299 infants with bronchiolitis 1 year (intervention and control hospitals) and 1689 infants 2 years post-trial (intervention hospitals). Adherence with no use of the five low-value practices 2 years post-trial completion was 80.9% (adjusted predicted adherence, 80.8%, 95% CI: 77.4% to 84.2%; estimated risk difference from cRCT outcome -3.9%, 95% CI: -8.6% to 0.8%) at intervention hospitals, fulfilling the a priori definition of sustainability. DISCUSSION: Targeted interventions, delivered over one bronchiolitis season, resulted in sustained improvements in bronchiolitis management in infants 2 years later. This follow-up study provides evidence for sustainability in de-implementing low-value care in bronchiolitis management. TRIAL REGISTRATION DETAILS: Australian and New Zealand Clinical Trials Registry No: ACTRN12621001287820.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.